Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?Benzinga • 8 days ago
Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lymphoma, demonstrating higher efficacy and tolerability than nanatinostat...
Share to Feed
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy...
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on iTeos Therapeutics (ITOS Research Report), Viracta Therapeutics...
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from...
Shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX Get Free Report) traded down 8.4% during trading on Thursday . The stock traded as low as $0.76 and last traded at $0.82. 190,182 shares were...
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter...
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viracta Therapeutics (VIRX Research Report) and Pa...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...